Metoprolol tartrate vs metoprolol succinate
Pro Research Analysisby 
Searched over 200M research papers
Metoprolol Tartrate vs. Metoprolol Succinate: A Comparative Analysis
Introduction to Metoprolol Formulations
Metoprolol is a beta-blocker commonly used to treat various cardiovascular conditions, including hypertension, heart failure, and angina. It is available in two formulations: metoprolol tartrate (MT) and metoprolol succinate (MS). While both forms are effective, they differ in their pharmacokinetic properties, dosing schedules, and clinical outcomes.
Hemodynamic Effects in Heart Failure
Hemodynamic Benefits and Adverse Effects
Both MT and MS have been shown to produce significant hemodynamic benefits in patients with congestive heart failure. A study comparing the two formulations found no significant difference in the hemodynamic response between MT and MS over a three-month period. Both formulations led to a decrease in cardiac index and stroke volume index, and an increase in systemic vascular resistance . This suggests that both MT and MS are equally effective in managing heart failure from a hemodynamic perspective.
Cardiac Function in Chronic Heart Failure
Heart Rate and Cardiac Function
In patients with chronic congestive heart failure, MS has been found to decrease the average heart rate more effectively than MT. However, there were no significant differences between the two formulations in terms of left ventricular end-diastolic diameter (LVDd), ejection fraction (EF), blood urea nitrogen (BUN), and creatinine (Crea) levels . This indicates that while MS may offer better heart rate control, both formulations are equally effective in maintaining overall cardiac and renal function.
Blood Pressure Control in Hypertension
Efficacy and Safety
In the treatment of mild hypertension, both MT and MS have shown high efficacy in lowering blood pressure. A study comparing the two formulations found no significant difference in the rate of achieving target blood pressure goals. However, MS was more effective in reducing the morning blood pressure peak and increasing heart rate variability . This suggests that MS may offer additional benefits in managing blood pressure fluctuations throughout the day.
Acute Myocardial Infarction
Heart Rate Reduction
In patients with acute myocardial infarction, both MT and MS were effective in reducing heart rates. However, there was no significant difference in the degree and trend of heart rate reduction between the two groups over the first 72 hours of treatment . This indicates that both formulations are equally effective in the acute management of heart rate in myocardial infarction patients.
Chronic Obstructive Pulmonary Disease (COPD) with Heart Failure
Cardiac Function Improvement
In patients with COPD complicating chronic heart failure, MS was found to be more effective than MT in improving cardiac function. However, both formulations showed similar safety profiles and no significant differences in lung function or quality of life scores . This suggests that MS may be the preferred option for improving cardiac function in this patient population.
Pharmacokinetic and Pharmacodynamic Properties
Controlled-Release Benefits
MS, particularly in its controlled-release form, offers more stable plasma concentrations and a more consistent beta-1 blockade over a 24-hour period compared to MT. This results in fewer plasma peaks and troughs, making MS a more convenient and potentially more effective option for long-term management 89.
Conclusion
Both metoprolol tartrate and metoprolol succinate are effective in managing various cardiovascular conditions. While they share many similarities in terms of efficacy and safety, MS offers some advantages in terms of heart rate control, blood pressure stability, and convenience of dosing. Therefore, the choice between MT and MS should be tailored to the specific needs and conditions of the patient.
Sources and full results
Most relevant research papers on this topic